CBD shows promise in the treatment of anxiety — but more research is needed, particularly among women
Marijuana Stocks, Finance, & InvestingUncategorized June 2, 2021 MJ Shareholders
A new report published in the journal Cannabis and Cannabinoid Research presents an overview of the clinical findings concerning the effectiveness of cannabidiol (CBD) in the treatment of anxiety. While the report suggests that CBD may offer a safe and effective treatment for anxiety, the authors highlight the need for additional research among the female population.
The research team behind the review, led by Madison Wright, notes that anxiety disorders are the most common mental health disorders worldwide. Despite the pervasiveness of anxiety disorder diagnoses, existing behavioral treatments offer limited effectiveness and the current pharmacological treatments carry unwanted negative consequences.
A growing research trend has focused on the anti-anxiety properties of cannabidiol (CBD) — a compound found in the Cannabis plant. Unlike tetrahydrocannabinol (THC), CBD does not produce a “high”, and studies have yet to uncover any evidence of abuse or dependence in humans.
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
